EBC - ON DEMAND
Next Generation – The Nile SIR, dedicated Sirolimus Stent The Indian Registry, Experience and Results
European Bifurcation Club 2015 – EBC 2015 – Athens, Greece
Dedicated bifurcation stents 1
Next Generation – The Nile SIR, dedicated Sirolimus Stent The Indian Registry, Experience and Results
Author: Gregory Pavlides, MD, PhD, University of Nebraska Medical Center, Omaha, USA
CONCLUSION
- Preliminary results with the novel Nile SIR technology, incorporating the Nile dedicated bifurcation platform with biodegradable-polymer as drug- carrier, and sirolimus as anti-proliferative agent, demonstrated favorable results in the treatment of complex bifurcation lesions, including high angiographic and procedural success (97.3%) and good safety results.
- Initial assessment of efficacy at 6 months follow-up showed high efficacy in inhibiting neointimal hyperplasia within the bifurcation anatomy, as demonstrated by the relatively low late lumen loss – a surrogate of neointimal hyperplasia, comparable to the current best-in-class “limus” devices.
- Results from ongoing registry expected in order to confirm these promising results.